KALA BIO (KALA)

Last close As at 02/10/2025

USD1.54

0.18 (13.24%)

Market capitalisation

USD11m

KALA BIO is a clinical-stage biotechnology company advancing its proprietary mesenchymal stem cell secretome (MSC-S) platform towards rare eye diseases, with lead candidate KPI-012 targeting ocular surface diseases.

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Todd Bazemore

    CEO

  • Mary Reumuth

    CFO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free